Machine Learning Model Performance for Predicting Contrast Induced Nephropathy in Coronary InterventionsMachine learning models help predict kidney damage during heart procedures

Contrast-induced nephropathy (CIN) remains a significant clinical concern for patients undergoing coronary interventions. Given the complexity of identifying high-risk patients, advanced computational methods are being integrated into clinical workflows. This meta-analysis evaluates the predictive accuracy of various machine learning (ML) architectures to identify patients at risk for acute kidney injury following contrast exposure.

The study analyzed an extensive dataset comprising over 2 million patients, providing a robust foundation for evaluating model performance. The pooled incidence of CIN was determined to be approximately 11% (95% CI: 9-13%). This high prevalence underscores the clinical necessity for reliable predictive tools in interventional cardiology settings.

Among the various algorithms tested, Random Forest (RF) demonstrated superior performance with a reported area under the curve of 0.86 (95% CI: 0.85-0.87). While training datasets often show inflated performance metrics—with some models reaching AUCs near 0.98—the transition to test and external validation sets provides a more realistic view of clinical utility. Gradient Boosting Machines (GBM) and Extreme Gradient Boosting (XGBoost) also showed significant predictive capabilities, with pooled results indicating an AUC of 0.79. Ensemble models, which combine multiple learning techniques, achieved an AUC of 0.80 in test datasets, though these figures were associated with wider confidence intervals, suggesting more variability in performance across different cohorts.

When comparing ML models against traditional clinical markers, the ESUR criteria demonstrated a predictive accuracy comparable to several advanced models, yielding an AUC of 0.77 (95% CI: 0.72-0.82). This suggests that while machine learning offers sophisticated data processing, established clinical guidelines remain robust tools for risk stratification.

External validation is critical for the implementation of these tools in daily practice. The pooled AUC for externally validated models was 0.77 (95% CI: 0.71-0.84). This indicates that while ML models like RF and XGBoost are effective, their performance can vary depending on the specific population and data characteristics used during the validation phase.

Clinicians should view these machine learning tools as supportive decision-making aids rather than definitive diagnostic replacements. The integration of Random Forest and Ensemble models into clinical pathways may help identify high-risk patients more effectively than standard methods alone, allowing for proactive management of renal risk during coronary interventions.